|Bid||0.0000 x 4000|
|Ask||0.0000 x 1000|
|Day's Range||5.3200 - 5.4600|
|52 Week Range||3.4000 - 21.6600|
|Beta (3Y Monthly)||-1.95|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.03 (0.57%)|
|1y Target Est||30.00|
Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the appointment of Robert J. Michel, CPA, MBA as its new chief financial officer, effective September 28, 2018. “Bob joins Daxor with significant experience across a wide array of industries, including serving on the board of a biometric solutions company . In addition, his public company expertise, combined with his comfort in working and communicating with the investor public make him an important addition to the Daxor team,” commented Michael Feldschuh, CEO of Daxor Corporation.
Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement, today announced that Michael Feldschuh, chief executive officer of Daxor, will be a featured presenter at The MicroCap Conference on Tuesday, October 2, 2018 at 4:30 PM ET. Daxor Corporation is an innovative medical instrumentation and biotechnology company.
Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the presentation of two Mayo Clinic studies showing that direct blood volume analysis provides doctors with important information to inform treatment, and does so at an advantage over surrogate measurements, including cardiac filling pressure and kidney function. The studies were presented Saturday, September 15, 2018 at the 22nd Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Nashville, Tenn. “In each study, we compared blood volume analysis to a surrogate marker to understand the best way to treat heart failure and, in one study, heart failure with accompanying kidney disease.
Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be attending the 22nd Annual Scientific Meeting of the Heart Failure Society of America (HFSA) at the Gaylord Opryland Hotel and Convention Center in Nashville, TN from September 15-17th, 2018. “The HFSA’s Annual Scientific Meeting is a premier event that gathers the best scientific minds focused on heart failure research and outcomes.
Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations filed a Form N-CSR disclosing its schedule of portfolio holdings as of June 30, 2018. In reporting its mid-year results, Daxor Corporation has seen important developments in 2018 including a 23 percent rise in kit sales related to the use of its diagnostic device, the BVA-100 blood volume analyzer in the area of cardiology, which was driven by important data showing a substantial benefit using the BVA-100 in a study of 245 patients with hospitalized heart failure, Further, data was presented by investigators at the Mayo Clinic during the 2018 American College of Cardiology annual scientific meeting showing a 56 percent reduction in hospital readmissions and 82 percent reduction in mortality for patients measured on a 30-day basis when the BVA-100 test was used to guide treatment compared to a sampled control group.
Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the publication of an investigator-initiated study from Duke University and The Mayo Clinic demonstrating that despite the widespread use of formula-derived estimates of plasma volume in heart failure patients, these methods are inaccurate compared to measured volume using the company’s BVA-100 blood volume measurement diagnostic. The study, “Calculated Estimates of Plasma Volume in Patients with Chronic Heart Failure – Comparison to Measured Volumes” was recently published in the Journal of Cardiac Failure.
On Thursday, June 28, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Thursday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: Valeritas Holdings Inc. (NASDAQ: VLRX), Daxor Corp. (NYSE AMER: DXR), Endologix Inc. (NASDAQ: ELGX), and Glaukos Corp. (NYSE: GKOS).
Ahead of today's trading session, WallStEquities.com scans Daxor Corp. (NYSE AMER: DXR), Endologix Inc. (NASDAQ: ELGX), Glaukos Corp. (NYSE: GKOS), and Halyard Health Inc. (NYSE: HYH). Companies in the Medical Instruments and Supplies space manufacture and sell medical devices, instrument systems, and reagents and consumables.
While small-cap stocks, such as Daxor Corporation (AMEX:DXR) with its market cap of US$28.93M, are popular for their explosive growth, investors should also be aware of their balance sheet toRead More...
NEW YORK, NY / ACCESSWIRE / March 16, 2018 / Daxor shares were skyrocketing in Thursday trading with gains as high as over 130% after physician-researchers of Mayo Clinic presented new positive findings ...
NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
Daxor Corporation (AMEX:DXR) is a small-cap stock with a market capitalization of $19.48M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they endRead More...
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Daxor Corp. with the following peers – LeMaitre Vascular, Inc., Nephros, Inc. and CytoSorbents Corporation (LMAT-US, NEPH-US and CTSO-US). Daxor Corp.’s dividend yield is 0.63 percent and its dividend payout is 7.88 percent. This compares to a peer average dividend yield of 0.66 percent and ... Read more (Read more...)
After looking at Daxor Corporation’s (AMEX:DXR) latest earnings announcement (30 June 2017), I found it useful to revisit the company’s performance in the past couple of years and assess thisRead More...